Immunic, Inc.
IMUXHealthcareNASDAQBiotechnology · Last scanned Sep 7, 2026
Scan Results
Daily timeframeImmunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. With a market capitalization of $178.9M, it sits in micro-cap territory. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Market Cap
$178.9M
Beta
1.41
P/E (TTM)
—
P/E (Fwd)
-5.40
EPS (TTM)
$-3.55
EPS (Fwd)
$-2.43
ROE
-138.2%
ROA
-66.8%
Cash
$155.1M
Total Debt
$567,000
Free CF
-$51.4M
52W Change
58.5%
Annual Financials
Cash vs Debt
Where IMUX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, IMUX finished 14.19% above its 150-day moving average ($12.47) and 29.81% above its 200-day moving average ($10.97). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IMUX overbought or oversold?
At the September 3, 2026 close, IMUX's RSI(14) was 29.9, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Immunic, Inc. holds $155.1M in cash against $567K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$51.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -138.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, IMUX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing IMUX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.